Upstream Bio (NASDAQ:UPB – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.05, reports. Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%.The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.42 million.
Upstream Bio Stock Up 1.1%
Shares of UPB stock traded up $0.10 during mid-day trading on Wednesday, hitting $9.05. 452,327 shares of the company’s stock were exchanged, compared to its average volume of 1,059,633. Upstream Bio has a fifty-two week low of $7.25 and a fifty-two week high of $33.68. The stock has a market cap of $492.23 million, a price-to-earnings ratio of -3.37 and a beta of 1.28. The stock has a 50-day simple moving average of $9.17 and a two-hundred day simple moving average of $19.45.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on UPB. Weiss Ratings downgraded Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a research note on Friday, March 27th. Finally, Wall Street Zen downgraded Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Upstream Bio presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of Upstream Bio during the first quarter valued at approximately $115,000. Woodline Partners LP grew its holdings in shares of Upstream Bio by 5.8% during the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after purchasing an additional 30,552 shares during the last quarter. Creative Planning bought a new position in shares of Upstream Bio during the second quarter valued at approximately $154,000. JPMorgan Chase & Co. grew its holdings in shares of Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after purchasing an additional 1,275 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares during the last quarter.
Upstream Bio Company Profile
Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.
The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.
Featured Articles
- Five stocks we like better than Upstream Bio
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
